NCT01743950 2026-03-25
A Phase II Study of Pulse Reduced Dose Rate Radiation Therapy With Bevacizumab
University of Wisconsin, Madison
Phase 2 Terminated
Clinical Trials
88 trialsNCT07297212 2026-03-12
A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma
BioNTech SE
Phase 2 Recruiting
NCT07263438 2026-02-13
Phenix
Centre Hospitalier Universitaire Vaudois
Phase 2 Recruiting
NCT06061809 2026-02-12
N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma
ImmunityBio, Inc.
Phase 2 Recruiting
NCT05871021 2026-01-09
PRIDE
University Hospital Tuebingen
Phase 2 Recruiting
NCT03743662 2026-01-07
Nivolumab With Radiation Therapy and Bevacizumab for Recurrent MGMT Methylated Glioblastoma
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT03532295 2025-11-21
Retifanlimab and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent Gliomas
Washington University School of Medicine
Phase 2 Completed
NCT02974621 2025-08-03
Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04406272 2025-06-10
VB-111 in Surgically Accessible Recurrent/Progressive GBM
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT01903330 2025-03-05
ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme
Epitopoietic Research Corporation
Phase 2 Active not recruiting
NCT03452579 2025-02-28
Nivolumab Plus Standard Dose Bevacizumab Versus Nivolumab Plus Low Dose Bevacizumab in GBM
Case Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT01894061 2025-02-17
NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma
Case Comprehensive Cancer Center
Phase 2 Completed
NCT01814813 2025-01-24
Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery
Alliance for Clinical Trials in Oncology
Phase 2 Terminated
NCT06160206 2024-11-19
Retifanlimab with Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblastoma
Academic and Community Cancer Research United
Phase 2 Recruiting
NCT04952571 2024-10-15
Combined Treatment of Camrelizumab and Bevacizumab for Adult Patients with Recurrent Glioblastoma (GBM)
Beijing Sanbo Brain Hospital
Phase 2 Terminated
NCT01149850 2024-09-19
Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosarcoma
Jonsson Comprehensive Cancer Center
Phase 2 Completed
NCT03661723 2024-09-19
Pembrolizumab and Reirradiation in Bevacizumab Naïve and Bevacizumab Resistant Recurrent Glioblastoma
Dana-Farber Cancer Institute
Phase 2 Completed
NCT05638451 2024-06-05
Sintilimab in Combination With Bevacizumab and Temozolomide in Recurrent Glioblastoma (GBM) Patients
Zhujiang Hospital
Phase 2 Unknown
NCT04681677 2024-04-26
IORT
Xoft, Inc.
Phase 2 Terminated
NCT05540275 2023-10-06
Tislelizumab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for Bevacizumab Refractory Recurrent Glioblastoma
Henan Provincial People's Hospital
Phase 2 Not yet recruiting
NCT05191784 2023-06-12
GX-I7 in Combination With Bevacizumab in Recurrent Glioblastoma (GBM) Patients
Genexine, Inc.
Phase 2 Unknown
NCT01730950 2022-12-29
Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma
Radiation Therapy Oncology Group
Phase 2 Completed
NCT02336165 2022-10-12
Phase 2 Study of Durvalumab (MEDI4736) in Patients With Glioblastoma
Ludwig Institute for Cancer Research
Phase 2 Completed
NCT05502991 2022-09-27
Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNA-level-relapse and Clinical-relapse Glioblastoma
Henan Provincial People's Hospital
Phase 2 Not yet recruiting
NCT01609790 2022-07-21
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
National Cancer Institute (NCI)
Phase 2 Completed
NCT02663271 2022-06-23
TTFields and Pulsed Bevacizumab for Recurrent Glioblastoma
University of Florida
Phase 2 Terminated
NCT01004874 2022-04-13
Avastin/Radiation (XRT)/Temozolomide (Temodar) Followed by Avastin/Temodar/Topotecan for Glioblastoma
Duke University
Phase 2 Completed
NCT00805961 2021-12-08
RT, Temozolomide, and Bevacizumab Followed by Bevacizumab/Everolimus in First-line Treatment of GBM
SCRI Development Innovations, LLC
Phase 2 Completed
NCT00879437 2021-07-21
Valproic Acid, Radiation, and Bevacizumab in Children With High Grade Gliomas or Diffuse Intrinsic Pontine Glioma
Baylor College of Medicine
Phase 2 Completed
NCT02743078 2021-06-02
Optune® Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma
RTOG Foundation, Inc.
Phase 2 Terminated
NCT00590681 2021-03-30
Bevacizumab and Temozolomide Following Radiation and Chemotherapy for Newly Diagnosed Glioblastoma Multiforme
University of Chicago
Phase 2 Completed
NCT01740258 2021-01-26
BBP
Duke University
Phase 2 Completed
NCT02337491 2020-12-22
Pembrolizumab +/- Bevacizumab for Recurrent GBM
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00586508 2020-09-24
Trial of Enzastaurin and Bevacizumab in Participants With Recurrent Malignant Gliomas
Eli Lilly and Company
Phase 2 Completed
NCT01013285 2020-09-21
Bevacizumab, Temozolomide, and External Beam Radiation Therapy as First-Line Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
Jonsson Comprehensive Cancer Center
Phase 2 Completed
NCT00795665 2020-05-12
Bevacizumab and Carmustine in Treating Patients With Relapsed or Progressive High-Grade Glioma
University of California, Davis
Phase 2 Completed
NCT02342379 2020-04-10
TH-302 in Combination With Bevacizumab for Glioblastoma
The University of Texas Health Science Center at San Antonio
Phase 2 Completed
NCT01067469 2020-03-17
Standard Dose Bevacizumab Versus Low Dose Bevacizumab Plus Lomustine (CCNU) for Recurrent Glioblastoma Multiforme (GBM)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01478321 2020-03-12
Efficacy of Hypofractionated XRT w/Bev. + Temozolomide for Recurrent Gliomas
Northwestern University
Phase 2 Terminated
NCT01967810 2020-02-25
ANG1005 in Patients With Recurrent High-Grade Glioma
Angiochem Inc
Phase 2 Completed
NCT01498328 2020-02-17
ReACT
Celldex Therapeutics
Phase 2 Completed
NCT00337207 2020-02-07
Bevacizumab in Treating Patients With Recurrent or Progressive Glioma
Northwestern University
Phase 2 Completed
NCT02754362 2020-01-13
A Toll-like Receptor Agonist as an Adjuvant to Tumor Associated Antigens (TAA) Mixed With Montanide ISA-51 VG With Bevacizumab for Patients With Recurrent Glioblastoma
NYU Langone Health
Phase 2 Withdrawn
NCT00892177 2019-10-21
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT01564914 2019-06-12
105GM201
Tracon Pharmaceuticals Inc.
Phase 2 Completed
NCT02120287 2019-05-07
Border Zone Stereotactic Radiosurgery With Bevacizumab in Patients With Glioblastoma Multiforme
University of Pittsburgh
Phase 2 Completed
NCT01209442 2019-04-12
Hypofractionated Intensity-Modulated Radiation Therapy With Temozolomide and Bevacizumab for Glioblastoma Multiforme
University of Colorado, Denver
Phase 2 Completed
NCT01164189 2019-02-28
TAVAREC
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT01186406 2019-02-15
Gliadel, XRT, Temodar, Avastin Followed by Avastin, Temodar for Newly Diagnosed Glioblastoma Multiforme (GBM)
Duke University
Phase 2 Terminated
NCT00720356 2018-10-26
Bevacizumab and Erlotinib After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
Northwestern University
Phase 2 Completed